ArticleDermatology practical & conceptual2025
Family and Quality of Life Challenges in Mycosis Fungoides Patients: A Case-Control Study from Shiraz, Southern Iran.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Mycosis Fungoides/Sézary Syndrome on Patients' and Cohabitants' Quality of Life-A Cross-Sectional Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe quality of life (QoL) of patients suffering from cutaneous malignancies like cutaneous T-cell lymphoma (CTCL) and their family caregivers is widely affected by the disease and its treatment.
objectivesThis study aimed to evaluate the impact of the disease and its treatment on patients with MF and their families through self-administered questionnaires in our referral center in Shiraz.
methodsPatients with mycosis fungoides, the most common variant of CTCL, and one of their family members participated in this study by filling out the questionnaires on Dermatology Life Quality Index (DLQI) and Family Dermatology Life Quality Index (FDLQI). The World Health Organization Quality of Life Brief Version (WHOQOL-BREF) was also completed by patients and healthy controls.
resultsA total of 113 cases, 91 patients' relatives, and 129 healthy controls participated in this study. The mean DLQI total score was 8.00 ± 6.41. WHOQOL-BREF and/or their subdomains were ameliorated with advanced stage, active disease, increasing MSWAT score, early disease, the head/neck location, as well as interferon and gemcitabine. "Symptoms and feelings" and "leisure" dimensions of DLQI were the most affected, while regarding WHOQOL-BREF, the disease significantly impacted the "psychological", "environmental" and "general health" aspects (P<0.001, P=0.045, and P<0.001, respectively). Given the sociodemographic characteristics of the study participants, patients with a higher level of education suffered more (P=0.035).The FDLQI score was 8.44 ± 6.93, not affected by sex, relationship, or caregivers' education level. Family QoL deteriorated over the course of the disease (P=0.020), head/neck lesions (P= 0.003), less than 12 months duration (P=0.029), and interferon (P=0.034).
conclusionsDue to the distress that patients and caregivers experience during the first year of diagnosis, head/neck lesions, and specific treatment, appropriate measures to prevent unrealistic expectations and better coping mechanisms are recommended.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.